Subcutaneous administration of monoclonal antibodies in oncology

Geburtshilfe und Frauenheilkunde

Volumn 74, Issue 4, 2014, Pages 343-349

  Jackisch, C ^a   Muller V ^b   Maintz, C ^c   Hell, S ^d   Ataseven, B ^e  

^a Sanaklinikum Offenbach Obstetrics and Gynecology   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c Hamatologisch Onkologische Praxis   (Germany)

^d Medizinisch wissenschaftliche Beratung   (Germany)

^e KLINIKEN ESSEN MITTE   (Germany)

Author keywords

breast cancer; monoclonal antibodies; oncology; subcutaneous therapy; trastuzumab

Indexed keywords

ABAGOVOMAB; ALEMTUZUMAB; DENOSUMAB; DOCETAXEL; EPIRUBICIN; MONOCLONAL ANTIBODY; RECOMBINANT HYALURONIDASE; RITUXIMAB; TRASTUZUMAB; VELTUZUMAB;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; DOSE CALCULATION; DRUG BIOAVAILABILITY; DRUG DEGRADATION; DRUG EFFICACY; DRUG FORMULATION; DRUG PENETRATION; DRUG SAFETY; EXTRACELLULAR MATRIX; FOLLOW UP; HUMAN; INJECTION SITE REACTION; MEDICAL SPECIALIST; NEOPLASM; PATIENT PREFERENCE; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SUBCUTANEOUS TISSUE; SURVIVAL TIME; SYSTEMATIC REVIEW; TREATMENT DURATION;

EID: 84899829020     PISSN: 00165751     EISSN: 14388804     Source Type: Journal    
DOI: 10.1055/s-0034-1368173     Document Type: Article

References (33)

1. Website of the Deutschen Krebsgesellschaft. Brustkrebs - Erkrankungsverlauf. Online: http://www.krebsgesellschaft.de last access: 15.10.2013
2. Faderl S., Ferrajoli A., Wierda W. et al. Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence. Cancer: 2010; 116 2360 2365
3. Hale G., Rebello P., Brettman L. R. et al. Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia after intravenous or subcutaneous routes of administration. Blood: 2004; 104 948 955
4. MabCampath Alemtuzumab, Zusammenfassung des EPAR für die Öffentlichkeit. Online: http://www.ema.europa.eu/docs/de-DE/document- library/EPAR-Summary-for-the-public/human/000353/WC500025261.pdf last access: 04.12.2013
5. Aue G., Lindorfer M. A., Beum P. V. et al. Fractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia. Haematologica: 2010; 95 329 332
6. Davies A., Merli F., Mihaljevic B. et al. Pharmacokinetics, safety, and overall response rate achieved with subcutaneous administration of rituximab in combination with chemotherapy were comparable with those achieved with intravenous administration in patients with follicular lymphoma in the first-line setting: stage 1 results of the phase 3 SABRINA study (BO22334). Blood (ASH Annual Meeting Abstracts): 2012; 120 1629
7. Pressemitteilung F. Hoffmann-La Roche Ltd. vom 2. September 2013.
8. Stopeck A. T., Lipton A., Body J. J. et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol: 2010; 28 5132 5139
9. Fizazi K., Carducci M., Smith M. et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet: 2011; 377 813 822
10. Henry D. H., Costa L., Goldwasser F. et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol: 2011; 29 1125 1132
11. Smith M. R., Saad F., Coleman R. et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet: 2012; 379 39 46
12. DKG Interdisziplinäre S3-Leitlinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms. Langversion 3.0, Aktualisierung 2012. Online: http://www.krebsgesellschaft.de/download/S3-Brustkrebs-Update-2012-OL- Langversion.pdf
13. AGO Empfehlungen für die Diagnostik und Therapie von Patientinnen mit primärem und metastasiertem Brustkrebs, Version 2012.1D. Online: http://www.ago-online.de
14. Cardoso F., Harbeck N., Fallowfield L. et al. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol: 2012; 23 vi11 vi19
15. Dahabreh I. J., Linardou H., Siannis F. et al. Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials. Oncologist: 2008; 13 620 630
16. Harris C. A., Ward R. L., Dobbins A. et al. The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis. Ann Oncol: 2011; 22 1308 1317
17. Slamon D. J., Leyland-Jones B., Shak S. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med: 2001; 344 783 792
18. Valero V., Forbes J., Pegram M. D. et al. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. J Clin Oncol: 2011; 29 149 156
19. Wardley A. M., Pivot X., Morales-Vasquez F. Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. J Clin Oncol: 2010; 28 976 983
20. Fachinformation Herceptin®, Fassung vom Januar 2013.
21. Xgeva®,ZusammenfasungderMerkmaledesArzneimittels,Fassungvom11.09. 2012.Online:http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/document/ document-detail.jsp?webContentId=WC500110381&mid=WC0b01ac058009a3dc
22. Bittner B., Richter W. F., Hourcade-Potelleret F. et al. Development of a subcutaneous formulation for trastuzumab - nonclinical and clinical bridging approach to the approved intravenous dosing regimen. Arzneimittelforschung: 2012; 62 401 409
23. Haller F. Converting intravenous dosing to subcutaneous dosing with recombinant human hyaluronidase. Pharm Tech: 2007; 10 861 864
24. Watson D. Hyaluronidase. Br J Anaesth: 1993; 71 422 425
25. Bookbinder L. H., Hofer A., Haller M. F. et al. A recombinant human enzyme for enhanced interstitial transport of therapeutics. J Control Release: 2006; 114 230 241
26. Frost G. I. Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration. Expert Opin Drug Deliv: 2007; 4 427 440
27. Wynne C., Harvey V., Schwabe C. et al. Comparison of subcutaneous and intravenous administration of trastuzumab: A phase I/Ib trial in healthy male volunteers and patients with HER2-positive breast cancer. J Clin Pharmacol: 2013; 53 192 201
28. Pegram M., Hsu S., Lewis G. et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene: 1999; 18 2241 2251
29. Hourcade-Poterellet F., Lemenuel-Diot A., McIntyre C. et al. Use of a population pharmacokinetic approach for the clinical development of a fixed-dose subcutaneous formulation of trastuzumab. CPT Pharmacometrics Syst Pharmacol: 2014; 3 e87
30. Ismael G., Hegg R., Muehlbauer S. et al. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncol: 2012; 13 869 878
31. Melichar B., Stroyakovskiy D., Ahn J. N. et al. Pathological complete response to trastuzumab subcutaneous fixed-dose formulation in the HannaH study: Subgroup analysis of patient demographics and tumor characteristics and influence of body weight and serum trough concentration of trastuzumab. Präsentiert als Poster auf dem ESMO-Kongress in Wien 2012.
32. Pivot X., Gligorov J., Müller V. et al. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. Lancet Oncol: 2013; 14 962 970
33. De Cock E., Semiglazov V., Lopez-Vivanco G. et al. Time savings with trastuzumab subcutaneous vs. intravenous administration: a time-and-motion study. Präsentiert als Poster auf der International Breast Cancer Conference St. Gallen 2013, Abstract P209. 2013